TMCnet News
SEngine Precision Medicine to Present Data Related to the Predictive Value of PARIS® Test, an Organoid-based Drug Response Assay, for Cholangiocarcinoma Patients at 2020 AACR Virtual Meeting Session IISEATTLE, May 15, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived tumor-based organoids, today announced that data from a retrospective study summarizing the predictive value of the PARIS® Test for cholangiocarcinoma will be presented virtually as a poster session (abstract number 8026) at the 2020 AACR Virtual Meeting Session II, to be held June 22-24, 2020. The PARIS® Test is CLIA certified to provide an actionable report to oncologists as a tool for therapeutic decisions, ranking sensitivity to targeted, endocrine and chemotherapy agents. The AACR poster presentation summarizes the strong correlation between genomics, retrospective treatment outcomes and PARIS® Test drug sensitivity results based on a retrospective analysis of 17 cholangiocarcinoma patients. This study shows the feasibility of functional testing of organoids derived from cholangiocarcinoma patients’ tissue in a CLIA-certified diagnostic test. These results correlate well with genomically predicted drug sensitivities for all patients, as well as showed additional drug sensitivities beyond those predicted by genomics offering patients additional potential treatment options. For patients whose cancer progressed on previous treatments (n=3), 100% retrospective concordance was shown between organoid drug resistance and prior treatment outcomes. Each patient represents a mosaic of dru sensitivities, reflecting unique combinations of genetic and epigenetic alterations, and the PARIS® Test can identify the best personalized drug for them. Details related to the poster presentation are as follows: About PARIS® Test About SEngine Precision Medicine Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn. Contact: |